title: [Investigation of amylin level changes among obese patients at different glucose metabolic states and effects of rosiglitazone intervention].
abstract: OBJECTIVE
  To measure the changes in plasma amylin level among obese patients at different glucose  metabolic states, and to evaluate effects of rosiglitazone intervention on obese type 2 diabetes patients.
  
  
  METHODS
  A total of 92 obese patients were categorized into normal glucose tolerance group (Group A, n=31),  impaired glucose tolerance group (Group B, n=30), and type 2 diabetes group (Group C, n=31) according to oral  glucose tolerance test (OGTT) results. Within the new type 2 diabetes group, patients were further randomized  into 4 mg rosiglitazone treatment group and life style adjustment group. Body mass index (BMI) and waist  circumference of all the patients were measured, and their plasma amylin and true insulin levels measured by  radioimmunoassay and EIA.
  
  
  RESULTS
  Compared with Group A, both fasting and 30 minute glucose load plasma amylin  levels, and ΔAmylin30/ΔGlucose30 in Group B and C were lower. Compared with the life style adjustment group,  both fasting and 30 minute plasma amylin levels, and homeostasis model assessment for B cell function  (HOMA-B)  were higher in the group that received rosiglitazone treatment, but still lower than those in the Group A.
  
  
  CONCLUSIONS
  Pancreatic B cell function and amylin secretion were impaired in the abnormal metabolic states of  impaired glucose tolerance and type 2 diabetes patients. Rosiglitazone intervention helped to improve B cell  function and increase amylin level.
authors.affiliation: Department of Endocrinology, Peking University First Hospital, Beijing 100034, China. 139137109@qq.com
authors.forename: Ge-heng
authors.initials: GH
authors.lastname: Yuan
authors.forename: Wei-yan
authors.initials: WY
authors.lastname: Zhang
authors.forename: Yan
authors.initials: Y
authors.lastname: Hui
authors.forename: Xiao-hui
authors.initials: XH
authors.lastname: Guo
mesh_terms: D000328:Adult; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000150:complications / Q000188:drug therapy*; D005260:Female; D005947:Glucose / Q000378:metabolism; D005951:Glucose Tolerance Test; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D058228:Islet Amyloid Polypeptide / Q000097:blood*; D007515:Islets of Langerhans / Q000187:drug effects / Q000502:physiology; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood* / Q000150:complications; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000627:therapeutic use*
chemical_list: D007004:Hypoglycemic Agents; D058228:Islet Amyloid Polypeptide; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D005947:Glucose